Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-624-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.48 million
Profitability
Miscellaneous
Employees103
OptionableOptionable
Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions
What is Rigel Pharmaceuticals' stock symbol?
Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."
How were Rigel Pharmaceuticals' earnings last quarter?
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.16) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.16). The biotechnology company earned $1.79 million during the quarter, compared to analyst estimates of $0.30 million. View Rigel Pharmaceuticals' Earnings History.
When is Rigel Pharmaceuticals' next earnings date?
What price target have analysts set for RIGL?
7 brokerages have issued 1 year target prices for Rigel Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $8.2143 in the next twelve months. This suggests a possible upside of 242.3% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.
What is the consensus analysts' recommendation for Rigel Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.
What are Wall Street analysts saying about Rigel Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (2/1/2019)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating though are increasing our price target to $8 from $7.50. The primary drivers to our price target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count. Our valuation is currently driven wholly by fostamatinib (Tavalisse) with 77% contribution from our U.S. and E.U. projections for cIPT and 23% contribution from our U.S. and E.U. projections for AIHA." (1/23/2019)
- 3. Cantor Fitzgerald analysts commented, "We believe Rigel is poised to achieved meaningful commercial sales of TAVALISSE in immune thrombocytopenia. In addition to ITP, we see expansion opportunities in AIHA and IgAN. Valuation Summary We arrive at our 12-month price target of $9/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from fostamatinib for immune-related disorders." (1/23/2019)
Has Rigel Pharmaceuticals been receiving favorable news coverage?
News articles about RIGL stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.
Are investors shorting Rigel Pharmaceuticals?
Rigel Pharmaceuticals saw a drop in short interest in January. As of January 15th, there was short interest totalling 15,175,962 shares, a drop of 15.6% from the December 31st total of 17,983,182 shares. Based on an average daily volume of 2,516,474 shares, the days-to-cover ratio is currently 6.0 days. Currently, 9.5% of the shares of the stock are sold short. View Rigel Pharmaceuticals' Current Options Chain.
Who are some of Rigel Pharmaceuticals' key competitors?
Some companies that are related to Rigel Pharmaceuticals include Theravance Biopharma (TBPH), Myovant Sciences (MYOV), Innoviva (INVA), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Aimmune Therapeutics (AIMT), Uniqure (QURE), Nabriva Therapeutics (NBRV), Corcept Therapeutics (CORT), TherapeuticsMD (TXMD), Clovis Oncology (CLVS), Cambrex (CBM), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC) and Esperion Therapeutics (ESPR).
Who are Rigel Pharmaceuticals' key executives?
Rigel Pharmaceuticals' management team includes the folowing people:
- Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
- Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
- Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
- Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
- Dr. Thomas A. Raffin, Co-Founder (Age 72)
Who are Rigel Pharmaceuticals' major shareholders?
Rigel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.24%), Millennium Management LLC (4.13%), Tamarack Advisers LP (3.30%), Candriam Luxembourg S.C.A. (1.49%), Rhenman & Partners Asset Management AB (1.36%) and Hudson Bay Capital Management LP (1.26%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Eldon C Mayer III, Nelson Cabatuan, Raul R Rodriguez and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.
Which institutional investors are selling Rigel Pharmaceuticals stock?
RIGL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, D. E. Shaw & Co. Inc., Northern Trust Corp, MetLife Investment Advisors LLC, Virtu Financial LLC, Two Sigma Advisers LP, Squarepoint Ops LLC and California Public Employees Retirement System. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Nelson Cabatuan. View Insider Buying and Selling for Rigel Pharmaceuticals.
Which institutional investors are buying Rigel Pharmaceuticals stock?
RIGL stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Tamarack Advisers LP, Assenagon Asset Management S.A., Bank of America Corp DE, Geode Capital Management LLC, Candriam Luxembourg S.C.A., Rhenman & Partners Asset Management AB and Hudson Bay Capital Management LP. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.
How do I buy shares of Rigel Pharmaceuticals?
Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rigel Pharmaceuticals' stock price today?
One share of RIGL stock can currently be purchased for approximately $2.40.
How big of a company is Rigel Pharmaceuticals?
Rigel Pharmaceuticals has a market capitalization of $399.94 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.
What is Rigel Pharmaceuticals' official website?
How can I contact Rigel Pharmaceuticals?
Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]
MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
